Cannabis use and transition to psychosis in people at ultra-high risk

Psychological Medicine

Volumn 44, Issue 12, 2014, Pages 2503-2512

  Valmaggia, L R ^a,b   Day, F L ^a,b   Jones, C ^a,b   Bissoli, S ^a,b   Pugh, C ^a,b   Hall, D ^a,b   Bhattacharyya, S ^a,b   Howes, O ^a,b   Stone, J ^a,b   Fusar Poli, P ^a,b   Byrne, M ^a,b   McGuire, P K ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cannabis; psychosis; substance use; ultra high risk

Indexed keywords

CANNABIS;

ADULT; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MALE; PSYCHOSES, SUBSTANCE-INDUCED; PSYCHOTIC DISORDERS; RISK; YOUNG ADULT;

ADULT; CANNABIS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PSYCHOSES, SUBSTANCE-INDUCED; PSYCHOTIC DISORDERS; RISK; YOUNG ADULT;

EID: 84904858458     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291714000117     Document Type: Article

References (47)

1. Addington J, Case N, Saleem MM, Auther AM, Cornblatt BA, Cadenhead KS. (2013). Substance use in clinical high risk for psychosis: A review of the literature. Early Intervention in Psychiatry. Published online 14 November 2013. doi: 10.1111/eip.12100.
2. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. (2002). Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. British Medical Journal 325, 1212-1213. (Pubitemid 35398785)
3. Auther AM, McLaughlin D, Carrion RE, Nagachandran P, Correll CU, Cornblatt BA. (2012). Prospective study of cannabis use in adolescents at clinical high risk for psychosis: Impact on conversion to psychosis and functional outcome. Psychological Medicine 42, 2485-2497.
4. Barkus EJ, Stirling J, Hopkins RS, Lewis S. (2006). Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathology 39, 175-178.
5. Batalla A, Crippa JA, Busatto GF, Guimaraes FS, Zuardi AW, Valverde O, Atakan Z, McGuire PK, Bhattacharyya S, Martin-Santos R. (2013). Neuroimaging studies of acute effects of THC and CBD in humans and animals: A systematic review. Current Pharmaceutical Design. Published online 14 June 2013. doi: 10.2174/13816128113199990432.
6. Bhattacharyya S, Atakan Z, Martin-Santos R, Crippa JA, Kambeitz J, Prata D, Williams S, Brammer M, Collier DA, McGuire PK. (2012). Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of d-9-Tetrahydrocannabinol on midbrain and striatal function. Molecular Psychiatry 17, 1152-1155.
7. Bhattacharyya S, Crippa JA, Allen P, Martin-Santos R, Borgwardt S, Fusar-Poli P, Rubia K, Kambeitz J, OCarroll C, Seal ML, Giampietro V, Brammer M, Zuardi AW, Atakan Z, McGuire PK. (2012). Induction of psychosis by ?9-Tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Archives of General Psychiatry 69, 27-36.
8. Casadio P, Fernandes C, Murray RM, Di Forti M. (2011). Cannabis use in young people: The risk for schizophrenia. Neuroscience and Biobehavioural Reviews 35, 1779-1787.
9. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, Poulton R, Craig IW. (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: Longitudinal evidence of a gene x environment interaction. Biological Psychiatry 57, 1117-1127. (Pubitemid 40615773)
10. Chadwick B, Miller ML, Hurd YL. (2013). Cannabis use during adolescent development: Susceptibility to psychiatric illness. Frontiers in Psychiatry 4, 129.
11. Corcoran CM, Kimhy D, Stanford A, Khan S, Walsh J, Thompson J, Schobel S, Harkavy-Friedman J, Goetz R, Colibazzi T, Cressman V, Malaspina D. (2008). Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis. Schizophrenia Research 106, 286-293.
12. Di Forti M, Iyegbe C, Sallis H, Kolliakou A, Falcone MA, Paparelli A, Sirianni M, La Cascia C, Stilo SA, Marques TR, Handley R, Mondelli V, Dazzan P, Pariante C, David AS, Morgan C, Powell J, Murray RM. (2012). Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biological Psychiatry 72, 811-816.
13. Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, Handley R, Luzi S, Russo M, Paparelli A, Butt A, Stilo SA, Wiffen B, Powell J, Murray RM. (2009). High-potency cannabis and the risk of psychosis. British Journal of Psychiatry 195, 488-491.
14. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2013). National Report 2012: United Kingdom. EMCDDA: Lisbon.
15. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia LR, Barale F, Caverzasi E, McGuire PK. (2012). Predicting psychosis: Meta-Analysis of transition outcomes in individuals at high clinical risk. Archives of General Psychiatry 69, 220-229.
16. Gage SH, Zammit S, Hickman M. (2013). Stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population. F1000 Medicine Reports 5, 2.
17. Gill KE, Poe L, Azimov N, Ben-David S, Vadhan NP, Girgis R, Moore H, Cressman V, Corcoran CM. (2013). Reasons for cannabis use among youths at ultra high risk for psychosis. Early Intervention in Psychiatry. Published online 26 November 2013. doi: 10.1111/eip.12112.
18. Gonzalez-Pinto A, Alberich S, Barbeito S, Gutierrez M, Vega P, Ibanez B, Haidar MK, Vieta E, Arango C. (2011). Cannabis and first-episode psychosis: Different long-Term outcomes depending on continued or discontinued use. Schizophrenia Bulletin 37, 631-639.
19. Grech A, Van Os J, Jones PB, Lewis SW, Murray RM. (2005). Cannabis use and outcome of recent onset psychosis. European Psychiatry 20, 349-353. (Pubitemid 40978562)
20. Hall W, Degenhardt L. (2000). Cannabis use and psychosis: A review of clinical and epidemiological evidence. Australian and New Zealand Journal of Psychiatry 34, 26-34. (Pubitemid 34692842)
21. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen H-U, Van Os J. (2005). Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 330, 11.
22. Hermann D, Schneider M. (2012). Potential protective effects of cannabidiol on neuroanatomical alterations in cannabis users and psychosis: A critical review. Current Pharmaceutical Design 18, 4897-4905.
23. Jonsson F, Freeman J, Hinton M, Towle L, ODonnell J, Power P. (2004). Cannabis and psychosis: A clinical audit of the prevalence and persistence of cannabis use in first-episode psychosis patients attending the Lambeth Early Onset (LEO) service in London. Schizophrenia Research 70 (Suppl. 1), 72.
24. Konings M, Henquet C, Maharajh HD, Hutchinson G, Van Os J. (2008). Early exposure to cannabis and risk for psychosis in young adolescents in Trinidad. Acta Psychiatrica Scandinavica 118, 209-213.
25. Kristensen K, Cadenhead KS. (2007). Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Research 151, 151-154. (Pubitemid 46656299)
26. Lappin JM, Morgan KD, Valmaggia LR, Broome MR, Woolley JB, Johns LC, Tabraham P, Bramon E, McGuire PK. (2007). Insight in individuals with an at risk mental state. Schizophrenia Research 90, 238-244. (Pubitemid 46188522)
27. Macleod J, Oakes R, Copello A, Crome I, Egger M, Hickman M, Oppenkowski T, Stokes-Lampard H, Davey Smith G. (2004). Psychological and social sequelae of cannabis and other illicit drug use by young people: A systematic review of longitudinal, general population studies. Lancet 363, 1579-1588. (Pubitemid 38625660)
28. Miller P, Lawrie SM, Hodges A, Clafferty R, Cosway R, Johnstone EC. (2001). Genetic liability, illicit drug use, life stress and psychotic symptoms: Preliminary findings from the Edinburgh Study of People at High Risk for Schizophrenia. Social Psychiatry and Psychiatric Epidemiology 36, 338-342. (Pubitemid 32894736)
29. Moore THM, Zammit S, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M, Lewis G. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 370, 319-328. (Pubitemid 47094993)
30. Phillips LJ, Curry C, Yung AR, Yuen HP, Adlard S, McGorry PD. (2002). Cannabis use is not associated with the development of psychosis in an ultra high-risk group. Australian and New Zealand Journal of Psychiatry 36, 800-806. (Pubitemid 35469740)
31. Rapp C, Bugra H, Riecher-Rossler A, Tamagni C, Borgwardt S. (2012). Effects of cannabis use on human brain structure in psychosis: A systematic review combining in vivo structural neuroimaging and post mortem studies. Current Pharmaceutical Design 18, 5070-5080.
32. Rebgetz S, Conus P, Hides L, Kavanagh DJ, Cotton S, Schimmelmann BG, McGorry PD, Lambert M. (2013). Predictors of substance use reduction in an epidemiological first-episode psychosis cohort. Early Intervention in Psychiatry. Published online 24 July 2013. doi: 10.1111/eip.12067.
33. Rocchetti M, Crescini A, Borgwardt S, Caverzasi E, Politi P, Atakan Z, Fusar-Poli P. (2013). Is cannabis neurotoxic for the healthy brain?. A meta-Analytical review of structural brain alterations in non-psychotic users. Psychiatry and Clinical Neurosciences 67, 483-492.
34. Rubino T, Parolaro D. (2013). Cannabis abuse in adolescence and the risk of psychosis: A brief review of the preclinical evidence. Progress in Neuropsychopharmacology and Biological Psychiatry. Published online 31 July 2013. doi: 10.1016/j.pnpbp.2013.07.020.
35. Stefanis NC, Dragovic M, Power BD, Jablensky A, Castle D, Morgan VA. (2013). Age at initiation of cannabis use predicts age at onset of psychosis: The 7-To 8-year trend. Schizophrenia Bulletin 39, 251-254.
36. Stone JM, Fisher HL, Major B, Chisholm B, Woolley J, Lawrence J, Rahaman N, Joyce J, Hinton M, Johnson S, Young AH. (2014). Cannabis use and first-episode psychosis: Relationship with manic and psychotic symptoms, and with age at presentation. Psychological Medicine 44, 499-506.
37. Stowkowy J, Addington J. (2013). Predictors of a clinical high risk status among individuals with a family history of psychosis. Schizophrenia Research 147, 281-286.
38. Tosato S, Lasalvia A, Bonetto C, Mazzoncini R, Cristofalo D, De Santi K, Bertani M, Bissoli S, Lazzarotto L, Marrella G, Lamonaca D, Riolo R, Gardellin F, Urbani A, Tansella M, Ruggeri M; PICOS-VENETO Group. (2013). The impact of cannabis use on age of onset and clinical characteristics in first-episode psychotic patients. Data from the Psychosis Incident Cohort Outcome Study (PICOS). Journal of Psychiatric Research 47, 438-444.
39. United Nations Office on Drugs and Crime. (2013). World Drug Report 2013. UNODC: Vienna (http://www.unodc.org/unodc/secured/wdr/wdr2013/World-Drug- Report-2013. pdf
40. Valmaggia LR, Stahl D, Yung AR, Nelson B, Fusar-Poli P, McGorry PD, McGuire PK. (2013). Negative psychotic symptoms and impaired role functioning predict transition outcomes in the at-risk mental state: A latent class cluster analysis study. Psychological Medicine 43, 2311-2325.
41. Van der Meer FJ, Velthorst E, Meijer CJ, Machielsen MW, de Haan L. (2012). Cannabis use in patients at clinical high risk of psychosis: Impact on prodromal symptoms and transition to psychosis. Current Pharmaceutical Design 18, 5036-5044.
42. Van Nierop M, Janssens M; Genetic Risk and Outcome of Psychosis (GROUP) Investigators
43. Bruggeman R, Cahn W, de Haan L, Kahn RS, Meijer CJ, Myin-Germeys I, Van Os J, Wiersma D. (2013). Evidence that transition from health to psychotic disorder can be traced to semi-ubiquitous environmental effects operating against background genetic risk. PLOS ONE 8, e76690.
44. Van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. (2002). Cannabis use and psychosis: A longitudinal population-based study. American Journal of Epidemiology 156, 319-327. (Pubitemid 34857999)
45. Van Winkel R, Esquivel G, Kenis G, Wichers M, Collip D, Peerbooms O, Rutten B, Myin-Germeys I, Van Os J. (2010). Review: Genome-wide findings in schizophrenia and the role of gene-environment interplay. CNS Neuroscience and Therapeutics 16, 185-192.
46. Van Winkel R; Genetic Risk and OUtcome of Psychosis (GROUP) Investigators. (2011). Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: Sibling analysis and proband follow-up. Archives of General Psychiatry 68, 148-157.
47. Yung AR, Phillips LJ, McGorry PD, McFarlane CA, Francey S, Harrigan S, Patton GC, Jackson HJ. (1998). Prediction of psychosis. A step towards indicated prevention of schizophrenia. British Journal of Psychiatry Supplement 172, 14-20. (Pubitemid 28258893)